164 related articles for article (PubMed ID: 35285234)
1. Tandem Chemoimmunotherapy by a Cascade-Responsive Molecular Prodrug.
Yang Z; Luo X; Lin Y; Huang J; Lin H; Gao J
ACS Chem Biol; 2022 Apr; 17(4):762-767. PubMed ID: 35285234
[TBL] [Abstract][Full Text] [Related]
2. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
3. Transformable prodrug nanoplatform
Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
[No Abstract] [Full Text] [Related]
4. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
5. A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.
Wang J; Zhang H; Lv J; Zheng Y; Li M; Yang G; Wei X; Li N; Huang H; Li T; Qin X; Li S; Wu C; Zhang W; Liu Y; Yang H
Acta Biomater; 2023 Jul; 164():522-537. PubMed ID: 37072069
[TBL] [Abstract][Full Text] [Related]
6. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
8. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment.
Feng B; Zhou F; Hou B; Wang D; Wang T; Fu Y; Ma Y; Yu H; Li Y
Adv Mater; 2018 Sep; 30(38):e1803001. PubMed ID: 30063262
[TBL] [Abstract][Full Text] [Related]
9. Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy.
Zhang J; Zhang Y; Zhao B; Lv M; Chen E; Zhao C; Jiang L; Qian H; Huang D; Zhong Y; Chen W
ACS Appl Mater Interfaces; 2021 Dec; 13(49):58319-58328. PubMed ID: 34855343
[TBL] [Abstract][Full Text] [Related]
10. Phosphorous Dendron Micelles as a Nanomedicine Platform for Cooperative Tumor Chemoimmunotherapy via Synergistic Modulation of Immune Cells.
Zhan M; Qiu J; Fan Y; Chen L; Guo Y; Wang Z; Li J; Majoral JP; Shi X
Adv Mater; 2023 Jan; 35(3):e2208277. PubMed ID: 36300810
[TBL] [Abstract][Full Text] [Related]
11. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
Yao D; Wang Y; Bian K; Zhang B; Wang D
Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
[TBL] [Abstract][Full Text] [Related]
12. Codelivered Chemotherapeutic Doxorubicin
Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
[TBL] [Abstract][Full Text] [Related]
13. Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy.
Choi J; Shim MK; Yang S; Hwang HS; Cho H; Kim J; Yun WS; Moon Y; Kim J; Yoon HY; Kim K
ACS Nano; 2021 Jul; 15(7):12086-12098. PubMed ID: 34165970
[TBL] [Abstract][Full Text] [Related]
14. Prodrug-loaded semiconducting polymer hydrogels for deep-tissue sono-immunotherapy of orthotopic glioblastoma.
Zhu L; Wang X; Ding M; Yu N; Zhang Y; Wu H; Zhang Q; Liu J; Li J
Biomater Sci; 2023 Oct; 11(20):6823-6833. PubMed ID: 37623749
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
16. Dual-prodrug cascade activation for chemo/chemodynamic mutually beneficial combination cancer therapy.
Zhang X; Guo H; Zhang X; Shi X; Yu P; Jia S; Cao C; Wang S; Chang J
Biomater Sci; 2023 Jan; 11(3):1066-1074. PubMed ID: 36562486
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
20. Detachable Nanoparticle-Enhanced Chemoimmunotherapy Based on Precise Killing of Tumor Seeds and Normalizing the Growing Soil Strategy.
Wang L; Ding K; Zheng C; Xiao H; Liu X; Sun L; Omer R; Feng Q; Zhang Z
Nano Lett; 2020 Sep; 20(9):6272-6280. PubMed ID: 32787161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]